Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer
GTHX SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Tender Offer of G1 Therapeutics, Inc.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GTHX, PETQ on Behalf of Shareholders
G1 Therapeutics (GTHX) Reports Q2 Loss, Tops Revenue Estimates
G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights
Shareholder Alert: Ademi LLP investigates whether G1 Therapeutics, Inc. has obtained a Fair Price for its Public Shareholders
Why Is G1 Therapeutics (GTHX) Stock Up 66% Today?
Pharmacosmos Group to Acquire G1 Therapeutics
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
G1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025
Biotech Bombshell: G1 Therapeutics Stock Is Too Much of a Gamble
G1 Therapeutics Added to the Russell 2000® and 3000® Indexes
G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty
Why Is Cancer-Focused G1 Therapeutics Stock Trading Lower On Monday?
Why Is G1 Therapeutics (GTHX) Stock Down 56% Today?
G1 Therapeutics' breast cancer drug fails in late-stage trial
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
G1 Therapeutics to Participate in TD Cowen's 5th Annual Oncology Innovation Summit
G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses
2 Biotech Stocks to Watch Under $20
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (GTHX) Q1 2024 Earnings Call Transcript
G1 Therapeutics (GTHX) Reports Q1 Loss, Lags Revenue Estimates
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (GTHX) Q4 2023 Earnings Call Transcript
G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024
Why Is G1 Therapeutics (GTHX) Stock Down 45% Today?
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
G1 Therapeutics: New Financials And Big Data Readout Alert
G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics: Flying Low, Too Low
Best Penny Stocks To Buy? 4 To Watch With Big News This Week
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)